{"name":"Thomas M. Lietman","slug":"thomas-m-lietman","ticker":"","exchange":"","domain":"","description":"Thomas M. Lietman is a specialized pharmaceutical company focused on the development and commercialization of ophthalmic treatments. The company has one marketed drug, Difluprednate Ophthalmic, which is used for various eye conditions.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Difluprednate Ophthalmic","genericName":"Difluprednate Ophthalmic","slug":"difluprednate-ophthalmic","indication":"Post-operative inflammation following ocular surgery","status":"marketed"}]}],"pipeline":[{"name":"Difluprednate Ophthalmic","genericName":"Difluprednate Ophthalmic","slug":"difluprednate-ophthalmic","phase":"marketed","mechanism":"Difluprednate is a potent corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.","indications":["Post-operative inflammation following ocular surgery","Anterior uveitis","Inflammatory conditions of the anterior segment of the eye"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBhbmdqWlhLNTdXZGZPYnpuY2VfSm8yMjZjWWdSbkEzbElEU3MtZmNZUGJIMGEwMVMwSnhrck5fV3JjcUlQcmJRbDZkNUZaMFY0Ymd1d01FUi1lQUhaRl9abTYyODJnS0VXUXk4MVFWbUJXdjlm?oc=5","date":"2019-01-01","type":"pipeline","source":"American Academy of Ophthalmology","summary":"New Gains With Fungal Keratitis - American Academy of Ophthalmology","headline":"New Gains With Fungal Keratitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQYmVuUFhBa1dEc0R4UVNVc0lVY0dnWlpvZ0ZjaWJuakhfYlVyR3VQRGlCOTNtSVVxdjVNQVo1ZGFHNzRHUUhUNENWS0llREZFWXVlcGJwRVZhWjBGMTlzN3Zyc3pudlJUZXhZeEFsQ1ltaVhlUFJuWEZGWFh5LTBENVZwRWhDaDFU?oc=5","date":"2018-04-25","type":"pipeline","source":"The New York Times","summary":"Infant Deaths Fall Sharply in Africa With Routine Antibiotics (Published 2018) - The New York Times","headline":"Infant Deaths Fall Sharply in Africa With Routine Antibiotics (Published 2018)","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}